Dean L. Schorno - Nov 25, 2024 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role: EVP & Chief Financial Officer
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Stock symbol: RIGL
Transactions as of: Nov 25, 2024
Transactions value $: $0
Form type: 4
Date filed: 11/26/2024, 08:01 PM
Previous filing: Sep 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RIGL	Employee Stock Option (right to buy)	Award	$0	+6.25K		$0.00	6.25K	Nov 25, 2024	Common Stock	6.25K	$18.70	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met.
F2	The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met.

Content

The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met.

The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met.